101 related articles for article (PubMed ID: 14663021)
1. Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease.
Weiss SM; Benwell K; Cliffe IA; Gillespie RJ; Knight AR; Lerpiniere J; Misra A; Pratt RM; Revell D; Upton R; Dourish CT
Neurology; 2003 Dec; 61(11 Suppl 6):S101-6. PubMed ID: 14663021
[TBL] [Abstract][Full Text] [Related]
2. Identification of anti-Parkinson's Disease Lead Compounds from Aspergillus ochraceus Targeting Adenosin Receptors A
Hu L; Tian S; Wu R; Tong Z; Jiang W; Hu P; Xiao X; Zhang X; Zhou H; Tong Q; Lu Y; Huang Z; Chen Y; Zhang Y
ChemistryOpen; 2021 Jun; 10(6):630-638. PubMed ID: 34102706
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists.
Shinkre BA; Kumar TS; Gao ZG; Deflorian F; Jacobson KA; Trenkle WC
Bioorg Med Chem Lett; 2010 Oct; 20(19):5690-4. PubMed ID: 20801028
[TBL] [Abstract][Full Text] [Related]
4. Preclinical jockeying on the translational track of adenosine A2A receptors.
Barkhoudarian MT; Schwarzschild MA
Exp Neurol; 2011 Apr; 228(2):160-4. PubMed ID: 21211537
[No Abstract] [Full Text] [Related]
5. Pathophysiological roles for purines: adenosine, caffeine and urate.
Morelli M; Carta AR; Kachroo A; Schwarzschild MA
Prog Brain Res; 2010; 183():183-208. PubMed ID: 20696321
[TBL] [Abstract][Full Text] [Related]
6. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist.
Jaakola VP; Griffith MT; Hanson MA; Cherezov V; Chien EY; Lane JR; Ijzerman AP; Stevens RC
Science; 2008 Nov; 322(5905):1211-7. PubMed ID: 18832607
[TBL] [Abstract][Full Text] [Related]
7. Glutathione-Mediated Neuroprotective Effect of Purine Derivatives.
Matsumura N; Aoyama K
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685879
[TBL] [Abstract][Full Text] [Related]
8. A
Jacobson KA; Suresh RR; Oliva P
Int Rev Neurobiol; 2023; 170():1-27. PubMed ID: 37741687
[TBL] [Abstract][Full Text] [Related]
9. The discovery of a selective and potent A2a agonist with extended lung retention.
Åstrand AB; Lamm Bergström E; Zhang H; Börjesson L; Söderdahl T; Wingren C; Jansson AH; Smailagic A; Johansson C; Bladh H; Shamovsky I; Tunek A; Drmota T
Pharmacol Res Perspect; 2015 Jun; 3(3):e00134. PubMed ID: 26236482
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 3,4-Dihydropyrimidin-2(1H)-ones As a Novel Class of Potent and Selective A2B Adenosine Receptor Antagonists.
Crespo A; El Maatougui A; Biagini P; Azuaje J; Coelho A; Brea J; Loza MI; Cadavid MI; García-Mera X; Gutiérrez-de-Terán H; Sotelo E
ACS Med Chem Lett; 2013 Nov; 4(11):1031-6. PubMed ID: 24900602
[TBL] [Abstract][Full Text] [Related]
11. Novel Adenosine Receptor Antagonists for Treating Cancer and Immune-Related Disorders.
Sabnis RW
ACS Med Chem Lett; 2023 Dec; 14(12):1619-1620. PubMed ID: 38116425
[TBL] [Abstract][Full Text] [Related]
12. Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells.
Sacramento CQ; Fintelman-Rodrigues N; Dias SSG; Temerozo JR; Da Silva APD; da Silva CS; Blanco C; Ferreira AC; Mattos M; Soares VC; Pereira-Dutra F; Miranda MD; Barreto-Vieira DF; da Silva MAN; Santos SS; Torres M; Chaves OA; Rajoli RKR; Paccanaro A; Owen A; Bou-Habib DC; Bozza PT; Souza TML
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215969
[TBL] [Abstract][Full Text] [Related]
13. A
Merighi S; Borea PA; Varani K; Vincenzi F; Jacobson KA; Gessi S
Curr Med Chem; 2022; 29(24):4138-4151. PubMed ID: 34844537
[TBL] [Abstract][Full Text] [Related]
14. Emerging Nondopaminergic Medications for Parkinson's Disease: Focusing on A2A Receptor Antagonists and GLP1 Receptor Agonists.
Shang P; Baker M; Banks S; Hong SI; Choi DS
J Mov Disord; 2021 Sep; 14(3):193-203. PubMed ID: 34399565
[TBL] [Abstract][Full Text] [Related]
15. Exploration of chalcones and related heterocycle compounds as ligands of adenosine receptors: therapeutics development.
Matthee C; Terre'Blanche G; Legoabe LJ; Janse van Rensburg HD
Mol Divers; 2022 Jun; 26(3):1779-1821. PubMed ID: 34176057
[TBL] [Abstract][Full Text] [Related]
16. Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients.
Lee SJ; Ter Kuile FO; Price RN; Luxemburger C; Nosten F
PLoS One; 2017; 12(2):e0168780. PubMed ID: 28192434
[TBL] [Abstract][Full Text] [Related]
17. A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer.
Chen HR; Sherr DH; Hu Z; DeLisi C
BMC Med Genomics; 2016 Jul; 9(1):51. PubMed ID: 27475327
[TBL] [Abstract][Full Text] [Related]
18. Prolonged neuropsychiatric effects following management of chloroquine intoxication with psychotropic polypharmacy.
Maxwell NM; Nevin RL; Stahl S; Block J; Shugarts S; Wu AH; Dominy S; Solano-Blanco MA; Kappelman-Culver S; Lee-Messer C; Maldonado J; Maxwell AJ
Clin Case Rep; 2015 Jun; 3(6):379-87. PubMed ID: 26185633
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and tolerability of istradefylline for the treatment of restless legs syndrome: an exploratory study in five female patients.
Decerce J; Smith LF; Gonzalez W; Sussman NM
Curr Ther Res Clin Exp; 2007 Sep; 68(5):349-59. PubMed ID: 24692766
[TBL] [Abstract][Full Text] [Related]
20. Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro.
Janowsky A; Eshleman AJ; Johnson RA; Wolfrum KM; Hinrichs DJ; Yang J; Zabriskie TM; Smilkstein MJ; Riscoe MK
Psychopharmacology (Berl); 2014 Jul; 231(14):2771-83. PubMed ID: 24488404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
